Tesamorelin vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
A long-acting GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation for days with single injection.
Key Comparison Insights
- Tesamorelin is FDA approved, while CJC-1295 DAC remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to CJC-1295 DAC (Human Trials).
Detailed Comparison
| Attribute | Tesamorelin | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. | CJC-1295 DAC contains a reactive linker that binds to albumin after injection. This extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | Indefinite for approved indication | 8-12 weeks typical |
| Best Time to Take | Before bed (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients. | Studies show sustained 2-10 fold increase in GH levels lasting several days. Single weekly injection maintains elevated IGF-1. Less physiologic than pulsatile protocols but more convenient. |
Frequently Asked Questions: Tesamorelin vs CJC-1295 DAC
What is the difference between Tesamorelin and CJC-1295 DAC?
Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. new f8 formulation (egrifta wr) approved march 2025 allows weekly reconstitution vs daily. CJC-1295 DAC is a growth hormone peptide that a long-acting ghrh analog with drug affinity complex for extended half-life. provides sustained gh elevation for days with single injection. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.